Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 4/20 | 1.00 |
| ▸ | TDP2 | O95551 | 3/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 0.74 |
| ▸ | PADI1 | Q9ULC6 | 4/20 | 0.69 |
| ▸ | PADI3 | Q9ULW8 | 4/20 | 0.69 |
| ▸ | PADI4 | Q9UM07 | 4/20 | 0.69 |
| ▸ | PADI2 | Q9Y2J8 | 4/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.59 |
| ▸ | CES1 | P23141 | 1/20 | 0.59 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HKDC1 | Q2TB90 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599216 | 0.85 | S100A4 (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL4729919 | 0.81 | PADI1 (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL579998 | 0.75 | GAA (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL29551149 | 0.75 | GAA (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL30774319 | 0.75 | GAA (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL5915065 | 0.75 | TDP2 (0.81) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL460433 | 0.75 | TDP2 (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL29419580 | 0.75 | TDP2 (1.00) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL3275080 | 0.73 | TDP2 (0.95) | NSD2TDP2PAX8S100A4PADI1 | |
| SCHEMBL5915061 | 0.73 | GAA (0.86) | NSD2TDP2PAX8S100A4PADI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120091810-A | Methods and highly bioavailable permeable compounds for treating viral diseases | 基里尔·迪丹克 | 2025-06-03 | — | — | CN | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-11732286-B2 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732286-B2 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220170070-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220119858-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-21 | — | — | US | disclosed |
| US-11268129-B1 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-03-08 | — | — | US | disclosed |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010042500-A2 | HEAT SHOCK PROTEIN 90 INHIBITORS, METHODS OF PREPARING SAME, AND METHODS FOR THEIR USE | EMORY UNIVERSITY (US) | 2010-04-15 | — | — | WO | disclosed |
| US-6841555-B2 | Lavendamycin analogs, quinoline-5,8-diones and methods of using them | BALL STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | BALL STATE UNIVERSITY | 2004-12-09 | — | — | US | disclosed |
| US-6444684-B1 | ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR | BALL STATE UNIVERSITY | 2002-09-03 | — | — | US | disclosed |
| US-6030983-A | ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS | BALL STATE UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5712289-A | ANTITUMOR AGENTS, INTERMEDIATES FOR LAVENDAMYCINS | BALL STATE UNIVERSITY (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0701557-A4 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ MOHAMMAD (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5646150-A | ADMINISTERING AS ANTITUMOR AGENT, ANTIPROTOZOA AGENT, VIRICIDE, PARASITICIDE, OR BACTERICIDE | BALL STATE UNIVERSITY (US) | 1997-07-08 | — | — | US | disclosed |
| US-5525611-A | ANTITUMOR AGENT, BACTERICIDES, VIRICIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1996-06-11 | — | — | US | disclosed |
| EP-0701557-A1 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ, Mohammad (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029308-A1 | LAVENDAMYCIN ANALOGS, THEIR USE AND PREPARATION | BEHFOROUZ MOHAMMAD (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | NSD2 2340/4885TDP2 683/4885PAX8 4359/4885 |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | LSS, CYP51A1, COX5A | NSD2 3405/4885TDP2 2510/4885PAX8 3843/4885 |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AA1, HSP90AB2P | NSD2 4199/4885TDP2 707/4885PAX8 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.